AlphaMark Advisors’s Ocular Therapeutix OCUL Stock Holding History

AlphaMark Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-890	Closed	-$3K	–	509
2019 Q3	$3K	Buy	+890	New	+$3.98K	﹤0.01%	440

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaMark Advisors's OCUL Position: Q4 2019 in Review

AlphaMark Advisors sold out of Ocular Therapeutix (OCUL) in Q4 2019, closing a stake of 890 shares — an estimated $3K sold.

AlphaMark Advisors first reported a position in OCUL in Q3 2019 and held it in 1 quarter. The position peaked at $3K in Q3 2019. 79 funds tracked by Wall St. Rank hold OCUL as of Q4 2019.

AlphaMark Advisors reported no remaining Ocular Therapeutix position as of Q4 2019 after selling out during the quarter.
AlphaMark Advisors sold 890 Ocular Therapeutix shares in Q4 2019, an estimated $3K.
AlphaMark Advisors first reported a position in Ocular Therapeutix in Q3 2019 and held it in 1 quarter.
AlphaMark Advisors's Ocular Therapeutix position peaked at $3K in Q3 2019.
79 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2019.

Based on AlphaMark Advisors's 13F filing for Q4 2019, filed 7 Feb 2020.